Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Dong-Ho | - |
dc.contributor.author | Choi, Soul | - |
dc.contributor.author | Joung, Yoo Sook | - |
dc.contributor.author | Ha, Eun Hye | - |
dc.contributor.author | Kim, Boong-Nyun | - |
dc.contributor.author | Shin, Yee-Jin | - |
dc.contributor.author | Shin, Dongwon | - |
dc.contributor.author | Yoo, Hee Jeong | - |
dc.contributor.author | Cheon, Keun-Ah | - |
dc.date.available | 2021-02-22T10:57:58Z | - |
dc.date.issued | 2012-09 | - |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.issn | 1976-3026 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/6635 | - |
dc.description.abstract | Objective This study was aimed to determine effectiveness and tolerability of Osmotic-controlled Release Oral delivery (OROS) methylphenidate (MPH) and its optimal dose administered openly over a period of up to 12 weeks in drug naive Korean children with ADHD. Methods Subjects (n=143), ages 6 to 18-years, with a clinical diagnosis of any subtype of ADHD were recruited from 7 medical centers in Korea. An individualized dose of OROS-MPH was determined for each subject depending on the response criteria. The subjects were assessed with several symptom rating scales in week 1, 3, 6, 9 and 12. Results 77 of 116 subjects (66.4%) achieved the criteria for response and the average of optimal daily dose for response was to 30.05 +/- 12.52 mg per day (0.90 +/- 0.31 mg/kg/d) at the end of the study. Optimal dose was not significantly different between ADHD sub-types, whereas, significant higher dose was needed in older aged groups than younger groups. The average of optimal daily dose for response for the subjects aged above 12 years old was 46.38 +/- 15.52 per day (0.81 +/- 0.28 mg/kg/d) compared to younger groups (p<0.01). No serious adverse effects were reported and the dose did not have a significant effect on adverse effects. Conclusion Optimal mean dose of OROS-MPH was significantly different by age groups. Higher dose was needed in older aged groups than younger groups. Effectiveness and tolerability of OROS-MPH in symptoms of ADHD is sustained for up to 12 weeks. Psychiatry Investig 2012;9:257-262 | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN NEUROPSYCHIATRIC ASSOC | - |
dc.title | Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4306/pi.2012.9.3.257 | - |
dc.identifier.scopusid | 2-s2.0-84866666843 | - |
dc.identifier.wosid | 000309041400009 | - |
dc.identifier.bibliographicCitation | PSYCHIATRY INVESTIGATION, v.9, no.3, pp 257 - 262 | - |
dc.citation.title | PSYCHIATRY INVESTIGATION | - |
dc.citation.volume | 9 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 257 | - |
dc.citation.endPage | 262 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001741229 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | - |
dc.subject.keywordPlus | DEFICIT HYPERACTIVITY DISORDER | - |
dc.subject.keywordPlus | OROS METHYLPHENIDATE | - |
dc.subject.keywordPlus | ADOLESCENTS | - |
dc.subject.keywordAuthor | ADHD | - |
dc.subject.keywordAuthor | OROS-MPH | - |
dc.subject.keywordAuthor | Optimal dose | - |
dc.identifier.url | http://scholar.dkyobobook.co.kr/searchDetail.laf?barcode=4050026360800 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.